<DOC>
	<DOC>NCT00191035</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy, safety and tolerability of atomoxetine administered once daily in the treatment of adolescents with ADHD after 8 weeks and after 52 weeks</brief_summary>
	<brief_title>Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>Patients must have ADHD. Must be 1316 years of age. Must be able to swallow capsules. Expected to achieve score of 70 or more on IQ test Willing and reliable to keep appts. for clinic visits and test Treatment within last 30 days with a drug that has not received regulatory approval for any indication. Patients who weigh less than 40 kg or greater than 70 kg. Patients with documented history of Bipolar I or II disorder, or psychosis Patients with documented history of autism, asperger's syndrome or pervasive developmental disorder</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>December 2006</verification_date>
</DOC>